These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 1503818)

  • 1. Potential use of immunoconjugates for AIDS therapy.
    Kim YW; Chang TW
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1033-8. PubMed ID: 1503818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein.
    Pincus SH; Cole RL; Hersh EM; Lake D; Masuho Y; Durda PJ; McClure J
    J Immunol; 1991 Jun; 146(12):4315-24. PubMed ID: 1710247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoconjugates that neutralize HIV virions kill T cells infected with diverse strains of HIV-1.
    Kim YW; Fung MS; Sun NC; Sun CR; Chang NT; Chang TW
    J Immunol; 1990 Feb; 144(4):1257-62. PubMed ID: 2303707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for the use of immunotoxins in the treatment of HIV-infected humans.
    Van Oijen MG; Preijers FW
    J Drug Target; 1998; 5(2):75-91. PubMed ID: 9588864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4 toxin holds promise as treatment for HIV infection.
    Am Fam Physician; 1988 Nov; 38(5):355-6. PubMed ID: 3263790
    [No Abstract]   [Full Text] [Related]  

  • 6. Rational approach to AIDS drug design through structural biology.
    Wlodawer A
    Annu Rev Med; 2002; 53():595-614. PubMed ID: 11818491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein.
    Chaudhary VK; Mizukami T; Fuerst TR; FitzGerald DJ; Moss B; Pastan I; Berger EA
    Nature; 1988 Sep; 335(6188):369-72. PubMed ID: 2843774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the chemotherapy of AIDS.
    Verma S
    Indian J Physiol Pharmacol; 1994 Jan; 38(1):5-16. PubMed ID: 8132245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review. Drug resistance of human immunodeficiency virus and overcoming it by natural products.
    Hupfeld J; Efferth T
    In Vivo; 2009; 23(1):1-6. PubMed ID: 19368117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of oxyphenarsine as a potential antiviral agent for AIDS.
    Holland LE; Buthod JL; Kowal CD; Antonucci TK
    AIDS Res Hum Retroviruses; 1992 Sep; 8(9):1717-22. PubMed ID: 1457217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
    Rosenblum MG; Marks JW; Cheung LH
    Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Variants of HIV-2 and HIV-2 and approaches for chemotherapy of HIV infection].
    Rübsamen-Waigmann H
    Offentl Gesundheitswes; 1989; 51(8-9):562-6. PubMed ID: 2531353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunologic control of HIV-1 infection. Fantasy or soon reality?].
    Heiken H; Stoll M; Valor L; Weber K; Horvath T; Schmidt RE
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():50-4. PubMed ID: 15011590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
    Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
    Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evolution and Diversity of HIV-1].
    Metzner KJ
    Praxis (Bern 1994); 2011 Jan; 100(1):29-35. PubMed ID: 21210358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of AIDS with drugs targeted to inhibit different stages of the HIV life cycle.
    Sarin PS; Goldstein AL
    Immunopharmacol Immunotoxicol; 1995 May; 17(2):217-45. PubMed ID: 7650288
    [No Abstract]   [Full Text] [Related]  

  • 17. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
    Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
    Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM
    Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV pathogenesis: gp120-antibody complexes bind CD4 and kill T4 cells--immunotoxin therapy should prevent the progression of HIV to AIDS.
    Chaplin JW
    Med Hypotheses; 1999 Feb; 52(2):133-46. PubMed ID: 10340294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug failure during HIV-1 treatment. New perspectives in monitoring drug resistance.
    Re MC; Bon I; Monari P; Gorini R; Schiavone P; Gibellini D; La Placa M
    New Microbiol; 2003 Oct; 26(4):405-13. PubMed ID: 14596353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.